The Singapore-based medical device company has coated the new antibacterial sutures with triclosan, a broad-spectrum antimicrobial agent with activity against both gram-positive and gram-negative bacteria
China's NMPA approves Genesis MedTech’s absorbable sutures. (Credit: Van3ssa_ from Pixabay)
Genesis MedTech has secured approval from China’s National Medical Products Administration (NMPA) for the market launch of its absorbable sutures with antibacterial protection.
The Singapore-based medical device company has coated the new antibacterial sutures with triclosan, a broad-spectrum antimicrobial agent with activity against both gram-positive and gram-negative bacteria.
According to Genesis MedTech, its advanced sutures lower the risk of surgical site infections by suppressing the growth of Staphylococcus aureus and Staphylococcus epidermidis.
They also inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE), claimed the medical device company.
Genesis MedTech Group chairman and CEO Warren Wang said: “We are thrilled to achieve this significant milestone as the first domestic brand in China to develop antibacterial sutures. This pioneering innovation has immense potential to benefit numerous patients.
“Genesis will introduce more innovative products as part of the company’s roadmap, as we continue our mission to make quality healthcare more accessible for patients worldwide.”
Along with the absorbable antimicrobial sutures, Genesis MedTech plans to keep expanding its suture product lines with comprehensive offerings.
The firm received the NMPA’s certification for its barbed sutures in September 2022.
Genesis MedTech’s controlled-release needle sutures, non-absorbable surgical polypropylene sutures, and barbed absorbable sutures with black needle are said to be used widely.
The company’s product portfolio includes multi-therapy medical device products for emerging markets. It has sales and distributes products via its established commercial network.
Recently, the medical device firm secured Breakthrough Device designation from the US Food and Drug Administration (FDA) for its J-Valve Transfemoral (TF) System.
The J-Valve system is intended to treat severe native aortic regurgitation (AR) and AR-dominant mixed aortic valve disease in patients who are declared eligible for the device and are at high risk for open surgical aortic valve replacement.
Last year, the firm obtained FDA approval for its Chocolate Touch Drug-coated Balloon (DCB).